regn5458
regeneron pharmaceuticals
rrmm presenter naresh bumma provided compelling details from the first-in-human clinical study of regn5458, a bispecific antibody. the study findings noted an orr of 75% and 58% &gt;vgpr at higher doses with manageable tolerability and acceptable safety values. #ims2022 
To cure myeloma by fostering research, education and excellence in clinical care worldwide.